Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 18Myeloid 8Gastrointestinal 5Tumor-Agnostic 1Sarcoma 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Cholangiocarcinoma 2Biliary Tract Neoplasms 2Pancreatic Ductal Adenocarcinoma 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × ivosidenib × Gastrointestinal × Clear all
NCT07260175 2026-06-04

adIVO

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
16 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT04088188 2024-05-06

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Academic and Community Cancer Research United

Phase 1 Terminated
8 enrolled 14 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡